Anika Therapeutics, Inc. ANIK

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

Founded in 1992, Anika Therapeutics, Inc. ("Anika" or "Company") is a global leader in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The Company leverages proprietary hyaluronic acid ("HA") technology to develop highly differentiated products. Driven by strong partnerships with physicians, Anika is dedicated to pioneering HA-based innovations that redefine orthopedic care. Our mission is to restore active living, empower surgeon choice, and enhance patient outcomes worldwide.

"Together, we restore active living and redefine what's possible with hyaluronic acid."

Trust and Respect: We build trust and show respect in every interaction.

Quality: We are committed to quality as we work to improve people's lives.

Last close 21.27 2026-10-26
Market cap $284.7M 2026-06-30 share count
52-week range 9.01 - 22.88

Valuation FY2025 figures against the last close

P/S2.5x
P/E—
P/FCF65.3x
EV/EBITDA—
Dividend yield—
Diluted EPS-0.76

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Europe
  • Other Location
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 70.1M (62.1%) 62% United States Europe, FY2025: 22.2M (19.7%) 20% Europe Other Location, FY2025: 20.5M (18.2%) 18% Other Location FY2024 United States, FY2024: 82.4M (68.8%) 69% Europe, FY2024: 19.4M (16.2%) 16% Other Location, FY2024: 18.1M (15.1%) 15% FY2023 United States, FY2023: 86.9M (72.0%) 72% Europe, FY2023: 17.3M (14.3%) 14% Other Location, FY2023: 16.6M (13.7%) 14%
Region FY2025FY2024FY2023
United States $70.1M $82.4M $86.9M
Europe $22.2M $19.4M $17.3M
Other Location $20.5M $18.1M $16.6M

As the company reported it, from the “Note 13 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $112.8M$119.9M$120.8M$113.8M$147.8M$130.5M$114.6M$105.6M$113.4M$103.4M
Cost of revenue $49.0M$43.9M$38.3M$40.6M$64.9M$61.4M$28.7M$31.3M$27.4M$24.0M
Gross profit $63.8M$76.0M$82.5M$73.2M$82.9M$69.0M$85.9M$74.3M$86.1M$79.4M
R&D $25.8M$25.5M$21.8M$18.3M$27.3M$23.4M$16.7M$18.2M$18.8M$10.7M
SG&A $49.1M$55.6M$59.9M$51.2M$74.1M$60.1M$35.0M$34.3M$21.5M$18.0M
Total operating expenses $74.9M$81.1M$81.7M$69.5M$80.3M$97.3M$51.6M$52.5M$67.7M$52.8M
Operating income -$11.1M-$5.1M$844.0K$3.7M$2.6M-$28.3M$34.2M$21.7M$45.7M$50.6M
Pre-tax income -$9.3M-$2.8M$3.2M$4.3M$2.4M-$28.6M$36.1M$23.2M$46.2M$50.9M
Income tax $672.0K$6.1M$6.6M$2.1M$1.7M$4.6M$8.9M$4.5M$14.4M$18.3M
Net income -$11.0M-$56.0M-$83.0M-$15.0M$4.0M-$24.0M$27.2M$18.7M$31.8M$32.5M
EPS, basic -0.76-3.83-5.64-1.020.29-1.691.931.302.182.22
EPS, diluted -0.76-3.83-5.64-1.020.28-1.691.891.272.112.15
Shares, diluted (wtd. avg.) 14.3M14.7M14.7M14.8M14.6M14.2M14.4M14.7M15.1M15.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $57.5M$55.6M$68.7M$86.3M$94.4M$95.8M$157.5M$89.0M$133.3M$104.3M
Short-term investments $23.7M$23.6M$26.4M$34.6M$29.8M$2.5M$27.5M$70.0M$24.0M$20.5M
Receivables $23.7M$23.6M$26.4M$34.6M$29.8M$24.1M$23.1M$20.8M$23.8M$27.6M
Inventory $18.8M$23.8M$24.4M$39.8M$36.0M$46.2M$22.0M$21.3M$22.0M$16.0M
Total current assets $103.4M$113.7M$163.3M$169.5M$168.5M$177.4M$234.3M$202.9M$206.3M$170.4M
Property, plant and equipment $40.3M$39.0M$37.4M$48.3M$47.6M$50.6M$50.8M$54.1M$56.2M$52.3M
Goodwill $8.1M$7.1M$7.6M$7.3M$7.8M$8.4M$7.7M$7.9M$8.2M$7.2M
Other intangibles $1.6M$2.5M$2.6M$74.6M$82.4M$91.2M$7.6M$9.2M$10.6M$10.2M
Total assets $190.3M$202.7M$270.6M$349.1M$347.5M$365.6M$330.7M$279.0M$282.6M$240.2M
Accounts payable $6.0M$5.6M$6.2M$9.1M$7.6M$9.0M$3.8M$3.1M$6.7M$2.3M
Total current liabilities $21.9M$23.3M$31.1M$27.9M$29.8M$36.9M$16.3M$11.3M$13.1M$8.8M
Retained earnings $60.8M$71.7M$128.1M$210.7M$225.6M$221.4M$245.4M$218.2M$199.5M$168.2M
Total equity $143.5M$154.0M$212.3M$285.6M$287.1M$272.4M$288.4M$263.6M$263.5M$222.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $11.2M$5.4M-$1.8M$4.4M$8.4M$13.1M$37.0M$34.9M$40.8M$24.4M
Depreciation and amortisation $5.4M$5.0M$4.9M$4.9M$6.5M$6.1M$5.0M$4.9M$3.3M$2.7M
Stock-based compensation $10.1M$13.1M$15.2M$14.3M$11.1M$5.4M$6.1M$11.0M$5.8M$3.4M
Capital expenditure $6.8M$7.7M$5.4M$7.5M$5.1M$1.6M$2.8M$4.7M$9.0M$14.0M
Investing cash flow -$401.0K-$8.3M-$5.4M-$7.5M-$3.1M-$71.3M$39.7M-$50.3M-$12.5M-$6.8M
Financing cash flow -$10.6M-$12.7M-$6.3M-$4.9M-$6.8M-$3.8M-$8.1M-$28.9M$314.0K-$24.0M
Buybacks $9.5M$10.9M$5.0M$0$0$0$30.0M$30.0M—$25.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-017488.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -100M 0 100M 200M Revenue, FY2016: 103.4M Gross profit, FY2016: 79.4M Net income, FY2016: 32.5M Revenue, FY2017: 113.4M Gross profit, FY2017: 86.1M Net income, FY2017: 31.8M Revenue, FY2018: 105.6M Gross profit, FY2018: 74.3M Net income, FY2018: 18.7M Revenue, FY2019: 114.6M Gross profit, FY2019: 85.9M Net income, FY2019: 27.2M Revenue, FY2020: 130.5M Gross profit, FY2020: 69M Net income, FY2020: -24M Revenue, FY2021: 147.8M Gross profit, FY2021: 82.9M Net income, FY2021: 4M Revenue, FY2022: 113.8M Gross profit, FY2022: 73.2M Net income, FY2022: -15M Revenue, FY2023: 120.8M Gross profit, FY2023: 82.5M Net income, FY2023: -83M Revenue, FY2024: 119.9M Gross profit, FY2024: 76M Net income, FY2024: -56M Revenue, FY2025: 112.8M Gross profit, FY2025: 63.8M Net income, FY2025: -11M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $103.4M $113.4M $105.6M $114.6M $130.5M $147.8M $113.8M $120.8M $119.9M $112.8M
Gross profit $79.4M $86.1M $74.3M $85.9M $69.0M $82.9M $73.2M $82.5M $76.0M $63.8M
Net income $32.5M $31.8M $18.7M $27.2M -$24.0M $4.0M -$15.0M -$83.0M -$56.0M -$11.0M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.42B 36.4x 11.2%
MMM 3M CO $89.11B 28.8x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.06B 23.5x 19.9%
BDX BECTON DICKINSON & CO $53.49B 33.7x 8.2%
RMD RESMED INC $36.52B 24.3x 9.9%
DXCM DEXCOM INC $29.65B 37.6x 15.6%
MDLN Medline Inc. $28.86B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.78B 58.1x 6.3%